Information to be requested from all CA17104 participants:

Indicate your Working Group(s)

in COST **Action17104:**

First Name:

Surname:

Department

Primary Institution

Institution


Other institutions

Telephone:

e-mail:

Link to webpage

with biography:



optional

Link to webpage	
with group	optional
description:	

optional
In vitro and in vivo models of cancer multidrug resistance; combination strategies for overcoming multidrug resistance, preclinical testing of natural and synthetic compounds; mechanistical studies
General molecular biology laboratories; Cell culture facility; Zebrafish unit; Multiskan Spectrophotometer; xCELLigence system; Real-time PCR; Western blot system; Flow cytometer; Fluorescent microscope; Confocal Microscope
Human cancer cellular MDR models: non- small cell lung carcinoma, NCI-H460/R established by continuous treatment with doxorubicin; colorectal carcinoma, DLD1- TxR, and glioblastoma, U87-TxR established by continuous treatment with paclitaxel; anaplastic thyroid carcinoma - ATC, Rho-, established by cell sorting of the 8505C population with the lowest accumulation of the Rhodamine 123 (a P- gp and BCRP fluorescent substrate)

NOTE: By submitting this form to the Grant Manager of CA17104, I agree that this information can be used within the scope of this COST Action (e.g. may be included on the webpage of CA17104).